Panel Develops Criteria for Appropriate Use of PICCs

This article originally appeared here.
Share this content:
Panel Develops Criteria for Appropriate Use of PICCs
Panel Develops Criteria for Appropriate Use of PICCs

THURSDAY, Sept. 17, 2015 (HealthDay News) -- An expert panel has developed the Michigan Appropriateness Guide for Intravenous Catheters (MAGIC), according to research published in the Sept. 15 issue of the Annals of Internal Medicine.

Vineet Chopra, M.D., of the University of Michigan in Ann Arbor, and colleagues convened an expert panel that applied the RAND/UCLA Appropriateness Method to define criteria for the insertion, maintenance, and care of peripherally inserted central catheters (PICCs). After systematic reviews of the literature, scenarios were developed, and the appropriateness of PICC use was compared with that of other venous access devices.

The researchers found that 253 of 665 scenarios (38 percent) were rated as appropriate, 124 (19 percent) as neutral/uncertain, and 288 (43 percent) as inappropriate. For peripherally compatible infusions, when the proposed duration of use was five or fewer days, use of PICCs was rated as inappropriate. For use between six and 14 days, midline and ultrasonography-guided peripheral intravenous catheters were preferred to PICCs. In critically ill patients, when 14 or fewer days of use were likely, nontunneled central venous catheters were preferred over PICCs. In patients with cancer, for irritant or vesicant infusion, regardless of duration, PICCs were rated as appropriate.

"Although a key first step, these criteria offer but a blueprint of best practices," the authors write. "To make MAGIC truly happen, diffusion, uptake, and refinement from the providers and stakeholders engaged in vascular access is necessary."

Several authors report financial ties to the biomedical industry.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »